Prosecution Insights
Last updated: April 19, 2026

Examiner: REDWOOD, CHRISTOPHER EVAN

Tech Center 1600 • Art Units: 1629

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
7
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

8.0%
§101 Eligibility
8.0%
§102 Novelty
40.0%
§103 Obviousness
28.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18448559 COMBINATION THERAPIES FOR TREATMENT OF CIRRHOSIS WITH PORTAL HYPERTENSION Non-Final OA AstraZeneca AB
17923891 METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS Non-Final OA The Brigham and Women's Hospital, Inc.
18232970 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS Non-Final OA Incyte Corporation
18353770 BIARYL ETHER UREA COMPOUNDS Non-Final OA Jazz Pharmaceuticals Ireland Limited
18286068 COMPOUND FOR PREVENTING OR TREATING DIABETES Non-Final OA ONCOCROSS CO., LTD.
18230686 BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS Non-Final OA Chongqing Hongyuantang Medicine Co., Ltd.
18363123 ANTI-INFLAMMATORY COMPOSITION COMPRISING N-BENZYL-N-METHYLDECAN-1-AMINE OR A DERIVATIVE THEREOF AS AN ACTIVE INGREDIENT Non-Final OA HaYoung Meditech Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month